Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-02

Clinical Trial Update: 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for 68Ga-OPS202 imaging agent in gastroenteropancreatic neuroendocrine tumors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 68Ga-OPS202

Snippet

Sponsor: Ipsen | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-02